Page 432 - Williams Hematology ( PDFDrive )

406 Part V: Therapeutic Principles Chapter 25: Antithrombotic Therapy 407

29. Sconce EA, Khan TI, Wynne HA, et al: The impact of CYP2C9 and VKORC1 genetic 62. Linkins LA, Dans AL, Moores LK, et al: Treatment and prevention of heparin-induced
polymorphism and patient characteristics upon warfarin dose requirements: Proposal thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:
for a new dosing regimen. Blood 106(7):2329–2333, 2005. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
30. Schwarz UI, Ritchie MD, Bradford Y, et al: Genetic determinants of response to warfa- Chest 141(2 Suppl):e495S-e530S.
rin during initial anticoagulation. N Engl J Med 358(10):999–1008, 2008. 63. Rajgopal R, Bear M, Butcher MK, Shaughnessy SG: The effects of heparin and low
31. Wadelius M, Chen LY, Lindh JD, et al: The largest prospective warfarin-treated cohort molecular weight heparins on bone. Thromb Res 2008;122(3):293–298, 2012.
supports genetic forecasting. Blood 113(4):784–792, 2009. 64. van Den Belt AG, Prins MH, Lensing AW, et al: Fixed dose subcutaneous low molecular
32. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, et al: weight heparins versus adjusted dose unfractionated heparin for venous thromboem-
Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med bolism. Cochrane Database Syst Rev (2):CD001100, 2000.
360(8):753–764, 2009. 65. Donat F, Duret JP, Santoni A, et al: The pharmacokinetics of fondaparinux sodium in
33. Anderson JL, Horne BD, Stevens SM, et al: Randomized trial of genotype-guided ver- healthy volunteers. Clin Pharmacokinet 41(Suppl 2):1–9, 2002.
sus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 66. Parody R, Oliver A, Souto JC, Fontcuberta J: Fondaparinux (ARIXTRA) as an alter-
116(22):2563–2570, 2007. native anti-thrombotic prophylaxis when there is hypersensitivity to low molecular
34. Kimmel SE, French B, Kasner SE, et al: A pharmacogenetic versus a clinical algorithm weight and unfractionated heparins. Haematologica 88(11):ECR32, 2003.
for warfarin dosing. N Engl J Med 369(24):2283–2293, 2013. 67. Maraganore JM, Bourdon P, Jablonski J, et al: Design and characterization of hirulogs:
35. Pirmohamed M, Burnside G, Eriksson N, et al: A randomized trial of genotype-guided A novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990;29(30):
dosing of warfarin. N Engl J Med 369(24):2294–2303, 2013. 7095–7101, 2003.
36. Verhoef TI, Ragia G, de Boer A, et al: A randomized trial of genotype-guided dosing of 68. Warkentin TE, Greinacher A, Koster A: Bivalirudin. Thromb Haemost 99(5):830–839,
acenocoumarol and phenprocoumon. N Engl J Med 369(24):2304–2312, 2013. 2008.
37. Schulman S, Kearon C, Kakkar A, et al: Dabigatran versus warfarin in the treatment of 69. Berry CN, Girardot C, Lecoffre C, Lunven C: Effects of the synthetic thrombin inhibitor
acute venous thromboembolism. N Engl J Med 361(24):2342–2352, 2009. argatroban on fibrin- or clot-incorporated thrombin: Comparison with heparin and
38. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al: Oral rivaroxaban for symp- recombinant Hirudin. Thromb Haemost 72(3):381–386, 1994.
tomatic venous thromboembolism. N Engl J Med 363(26):2499–2510, 2010. 70. Swan SK, Hursting MJ: The pharmacokinetics and pharmacodynamics of argatroban:
39. EINSTEIN–PE Investigators, Büller HR, Prins MH, et al: Oral rivaroxaban for the treat- Effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 20(3):
ment of symptomatic pulmonary embolism. N Engl J Med 366(14):1287–1297, 2012. 318–329, 2000.
40. Pisters R, Lane DA, Nieuwlaat R, et al: A novel user-friendly score (HAS-BLED) to 71. Cardot JM, Lefevre GY, Godbillon JA: Pharmacokinetics of rec-hirudin in healthy volun-
assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart teers after intravenous administration. J Pharmacokinet Biopharm 22(2):147–156, 1994.
Survey. Chest 138(5):1093–1100, 2010. 72. Tripodi A, Chantarangkul V, Arbini AA, et al: Effects of hirudin on activated par-
41. Egred M, Rodrigues E: Purple digit syndrome and warfarin-induced skin necrosis. Eur tial thromboplastin time determined with ten different reagents. Thromb Haemost
J Intern Med 16(4):294–295, 2005. 70(2):286–288, 1993.
42. Warkentin TE, Sikov WM, Lillicrap DP: Multicentric warfarin-induced skin necrosis 73. Blech S, Ebner T, Ludwig-Schwellinger E, et al: The metabolism and disposition of the
complicating heparin-induced thrombocytopenia. Am J Hematol 62(1):44–48, 1999. oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36(2):386–
43. Marik PE, Plante LA: Venous thromboembolic disease and pregnancy. N Engl J Med 399, 2008.
359(19):2025–2033, 2008. 74. Hawes EM, Deal AM, Funk-Adcock D, et al: Performance of coagulation tests in
44. Ito S: Drug therapy for breast-feeding women. N Engl J Med 343(2):118–126, 2000. patients on therapeutic doses of dabigatran: A cross-sectional pharmacodynamic study
45. Douketis JD, Spyropoulos AC, Spencer FA, et al: Perioperative management of antith- based on peak and trough plasma levels. J Thromb Haemost 11(8):1493–1502, 2013.
rombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: 75. Schiele F, van Ryn J, Canada K, et al: A specific antidote for dabigatran: Functional and
American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. structural characterization. Blood 121(18):3554–3562, 2013.
Chest 141(2 Suppl):e326S–e350S. 76. Esnault P, Gaillard PE, Cotte J, et al: Haemodialysis before emergency surgery in a
46. Sarode R, Milling TJ Jr, Refaai MA, et al: Efficacy and safety of a 4-factor proth- patient treated with dabigatran. Br J Anaesth 111(5):776–777, 2013.
rombin complex concentrate in patients on vitamin K antagonists presenting with 77. van Ryn J, Schurer J, Kink-Eiband M, Clemens A: Reversal of dabigatran-induced
major bleeding: A randomized, plasma-controlled, phase IIIb study. Circulation bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of
2013;128(11):1234–1243, 2012. effect on assays of coagulation. Anesthesiology 120(6):1429–1440, 2014.
47. Baron TH, Kamath PS, McBane RD: Management of antithrombotic therapy in patients 78. Connolly SJ, Ezekowitz MD, Yusuf S, et al: Dabigatran versus warfarin in patients with
undergoing invasive procedures. N Engl J Med 368(22):2113–2124, 2013. atrial fibrillation. N Engl J Med 361(12):1139–1151, 2009.
48. Tafur AJ, McBane R 2nd, Wysokinski WE, et al: Predictors of major bleeding in 79. Friedman RJ, Dahl OE, Rosencher N, et al: Dabigatran versus enoxaparin for preven-
peri-procedural anticoagulation management. J Thromb Haemost 10(2):261–267, 2012. tion of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of
49. Birnie DH, Healey JS, Wells GA, et al: Pacemaker or defibrillator surgery without inter- three trials. Thromb Res 126(3):175–182, 2010.
ruption of anticoagulation. N Engl J Med 368(22):2084–2093, 2013. 80. Eikelboom JW, Connolly SJ, Brueckmann M, et al: Dabigatran versus warfarin in
50. Casu B, Oreste P, Torri G, et al: The structure of heparin oligosaccharide fragments patients with mechanical heart valves. N Engl J Med 369(13):1206–1214, 2013.
with high anti-(factor Xa) activity containing the minimal antithrombin III-bind- 81. Hillarp A, Baghaei F, Fagerberg Blixter I, et al: Effects of the oral, direct factor Xa inhib-
ing sequence. Chemical and 13C nuclear-magnetic-resonance studies. Biochem J itor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 9(1):133–
197(3):599–609, 1981. 139, 2011.
51. Damus PS, Hicks M, Rosenberg RD: Anticoagulant action of heparin. Nature 82. Francart SJ, Hawes EM, Deal AM, et al: Performance of coagulation tests in patients on
246(5432):355–357, 1973. therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on
52. Weitz JI, Hudoba M, Massel D, et al: Clot-bound thrombin is protected from inhibi- peak and trough plasma levels. Thromb Haemost 111(6):1133–1140, 2014.
tion by heparin-antithrombin III but is susceptible to inactivation by antithrombin III- 83. Patel MR, Mahaffey KW, Garg J, et al: Rivaroxaban versus warfarin in nonvalvular atrial
independent inhibitors. J Clin Invest 86(2):385–391, 1990. fibrillation. N Engl J Med 365(10):883–891, 2011.
53. de Swart CA, Nijmeyer B, Roelofs JM, Sixma JJ: Kinetics of intravenously administered 84. Eriksson BI, Borris LC, Friedman RJ, et al: Rivaroxaban versus enoxaparin for throm-
heparin in normal humans. Blood 60(6):1251–1258, 1982. boprophylaxis after hip arthroplasty. N Engl J Med 358(26):2765–2775, 2008.
54. Garcia DA, Baglin TP, Weitz JI, et al: Parenteral anticoagulants: Antithrombotic Ther- 85. Lassen MR, Ageno W, Borris LC, et al: Rivaroxaban versus enoxaparin for thrombopro-
apy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians phylaxis after total knee arthroplasty. N Engl J Med 358(26):2776–2786, 2008.
Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e24S-e43S. 86. Cohen AT, Spiro TE, Spyropoulos AC, et al: Rivaroxaban for thromboprophylaxis in
55. Cruickshank MK, Levine MN, Hirsh J, et al: A standard heparin nomogram for the acutely ill medical patients. N Engl J Med 368(20):1945–1946, 2013.
management of heparin therapy. Arch Intern Med 1991;151(2):333–337, 2012. 87. Prins MH, Lensing AW, Bauersachs R, et al: Oral rivaroxaban versus standard therapy
56. Levine MN, Hirsh J, Gent M, et al: A randomized trial comparing activated throm- for the treatment of symptomatic venous thromboembolism: A pooled analysis of the
boplastin time with heparin assay in patients with acute venous thromboembolism EINSTEIN-DVT and PE randomized studies. Thromb J 11(1):21, 2013.
requiring large daily doses of heparin. Arch Intern Med 154(1):49–56, 1994. 88. Wasserlauf G, Grandi SM, Filion KB, Eisenberg MJ: Meta-analysis of rivaroxaban and
57. Kearon C, Ginsberg JS, Julian JA, et al: Comparison of fixed-dose weight-adjusted bleeding risk. Am J Cardiol 112(3):454–460, 2013.
unfractionated heparin and low-molecular-weight heparin for acute treatment of 89. Levi M, Moore KT, Castillejos CF, et al: Comparison of three-factor and four-factor
venous thromboembolism. JAMA 296(8):935–942, 2006. prothrombin complex concentrates regarding reversal of the anticoagulant effects of
58. Cuker A, Gimotty PA, Crowther MA, Warkentin TE: Predictive value of the 4Ts scoring rivaroxaban in healthy volunteers. J Thromb Haemost 12(9):1428–1436, 2014.
system for heparin-induced thrombocytopenia: A systematic review and meta-analysis. 90. Perzborn E, Gruber A, Tinel H, et al: Reversal of rivaroxaban anticoagulation by hae-
Blood 120(20):4160–4167, 2012. mostatic agents in rats and primates. Thromb Haemost 110(1):162–172, 2013.
59. Weitz JI: Low-molecular-weight heparins. N Engl J Med 337(10):688–698, 1997. 91. Hillarp A, Gustafsson KM, Faxälv L, et al: Effects of the oral, direct factor Xa inhib-
60. Lim W, Dentali F, Eikelboom JW, Crowther MA: Meta-analysis: Low-molecular-weight itor apixaban on routine coagulation assays and anti-FXa assays. J Thromb Haemost
heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 12(9):1545–1553, 2014.
144(9):673–684, 2006. 92. Martin AC, Le Bonniec B, Fischer AM, et al: Evaluation of recombinant activated factor
61. Van Ryn-McKenna J, Cai L, Ofosu FA, et al: Neutralization of enoxaparine-induced VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban
bleeding by protamine sulfate. Thromb Haemost 63(2):271–274, 1990. in a rabbit model of bleeding and thrombosis. Int J Cardiol 168(4):4228–4233, 2013.

Kaushansky_chapter 25_p0393-0408.indd 407 9/19/15 12:20 AM